drugset
drugset / Trial / NCT06897111

Implantation of Cartilage Mini-grafts Made From Donor Cells to Treat Chondral Lesions of the Knee

NCT06897111 ↗

Phase 1/2 Active not recruiting 10 enrolled Vanarix SA
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and feasibility of implanting allogeneic cartilage mini-grafts (or allogenic Cartibeads) into cartilage defects in the knee. Allogeneic Cartibeads are engineered from allogeneic articular chondrocytes (from a donor's cartilage cells). The donor, who in 2022 participated in the Autologous Cartibeads clinical trial (Swissmedic ID 701146), consented to use his leftover cells for production of mini-grafts for other patients in this study. Our patented, standardized methodology allows production of bead-shaped mini-grafts (Allogeneic Cartibeads). These grafts are 1 to 2 mm in diameter and have similar characteristics to native hyaline cartilage. Allogeneic Cartibeads are implanted into the patient's cartilage defect. Patients are then followed for 6 months for assessment of study endpoints, with safety being the primary outcome.

Timeline

Start
2024-06-17
Primary completion
2025-07-01
Completion
2025-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Cartibeads Cell therapy — Other

Indications

No indication recorded.